简介：

张晓进，博士，教授，博士生导师，化学学院副院长。牛津大学访问学者。国家优秀青年科学基金获得者，江苏省杰青基金获得者，江苏省“333高层次人才培养工程”第二层次（中青年科技领军人才）。

长期从事创新药物研发及药物化学研究，主持国家及江苏省自然科学基金项目十余项，承担多项校企联合攻关项目。以通讯作者在Journalof the American Chemical Society、AngewandteChemie International Edition、Journalof Medicinal Chemistry (18)、EuropeanJournal of Medicinal Chemistry、ChineseChemical Letters、ChemicalScience、ChemicalCommunications、OrganicLetters等国际刊物发表论文80余篇；已授权中国、美国等国内外发明专利20余项，其中2个候选新药相关专利实现技术成果转化。曾获国家科技进步奖二等奖、教育部自然科学奖一等奖、江苏省科学技术一等奖、中国药学会青年药物化学奖。作为主要负责人设计研发的化药1类抗贫血新药在中国进入临床试验。

研究方向：

靶向氧感知通路的创新药物研发，化学创新驱动的新药发现

研究生招生专业：

药物化学（学博）、药学（专博）

药物化学（学硕）、化学（学硕）–化学生物学方向、药学（专硕）

实验室常用技术手段：

计算机辅助药物设计（CADD）、人工智能驱动的药物设计（AIDD）、量子化学计算；化学合成与结构表征；靶标水平活性测试方法构建；体内外PK/PD及安全性评价；临床前成药性评价等

团队老师：

        伍悦 副研究员

        杨付来 副教授

        董颖 副教授

代表性文章：

1.      A near-infraredphotoactivatable, brain-penetrant prodrug of the prolyl hydroxylaseinhibitor vadadustat for neuroprotection in ischemic stroke. Ke Li,Tiande Bing, Yikai Mo, Wenxuan Wang, Jihong Xing, Le Yang, Danni Ao,Zhihong Li, Fulai Yang, Yue Wu, Xiaojin Zhang. Journalof Medicinal Chemistry 2026, 69 (10),12702–12721 https://doi.org/10.1021/acs.jmedchem.6c01014

FrontCover: https://pubs.acs.org/toc/jmcmar/69/10

2.     Insights into HIFprolyl hydroxylase inhibitors: recent advances and expandingtherapeutic applications beyond anemia. Limin Wei, Yuqing Hu, YanlingLyu, Haixu Qian, Hanqing Qin, Yue Wu, Xiaojin Zhang. Journalof Medicinal Chemistry 2026,https://doi.org/10.1021/acs.jmedchem.6c01656

3.     Light-induced, lysine-targeting irreversible covalent inhibition ofthe human oxygen sensing hydroxylase factor inhibiting HIF (FIH). YueWu, Zhihong Li, Samanpreet Kaur, Zewei Zhang, Jie Yue, AnthonyTumber, Haoshu Zhang, Zhe Song, Peiyao Yang, Ying Dong, Fulai Yang,Xiang Li, Christopher J. Schofield, Xiaojin Zhang. Journalof the American Chemical Society 2025, 147 (21), 17871–17879(IF=14.5) https://doi.org/10.1021/jacs.5c01935

4.     Discovery of ZG-2305, an orally bioavailable factor inhibiting HIFinhibitor for the treatment of obesity and fatty liver disease. YueWu, Zewei Zhang, Haiping Cai, Weiqing Zhang, Linjian Zhang, ZhihongLi, Le Yang, Yafen Chen, Thomas Corner, Zhe Song, Jie Yue, FulaiYang, Xiang Li, Christopher J. Schofield, Xiaojin Zhang. Journalof Medicinal Chemistry 2025, 67 (16), 14668–14691https://doi.org/10.1021/acs.jmedchem.4c01698

Front Cover:https://pubs.acs.org/toc/jmcmar/68/1

5.     3-(Arylamido)pyrazolopyridine HIF-2α agonists and a codrug strategywith prolyl hydroxylase inhibition for synergistic treatment of renalanemia. Yinli Gao, Qingyun Yang, Simeng Liu, Jiaming Liu, Liwei Chen,Xiaoqian Bao, Linjian Zhang, Le Yang, Fulai Yang, Xiang Li, Yue Wu,Xiaojin Zhang. Journal of Medicinal Chemistry2025, 68 (23), 25569–25589https://doi.org/10.1021/acs.jmedchem.5c02719

6.      Asmall-molecule inhibitor of factor inhibiting HIF binding to atyrosine-flip pocket for the treatment of obesity. Yue Wu, YafenChen, Thomas Corner, Yu Nakashima, Eidarus Salah, Zhihong Li, LinjianZhang, Le Yang, Anthony Tumber, Zhuoli Sun, Yukang Wen, Ailin Zhong,Fulai Yang, Xiang Li, Zhihong Zhang, Christopher J. Schofield,Xiaojin Zhang. Angewandte Chemie InternationalEdition 2024, 63 (40), e202410438 (IF=16.1)https://doi.org/10.1002/anie.202410438

Cover:https://onlinelibrary.wiley.com/doi/10.1002/anie.202414504

7.     Preferred conformation-guided discovery of potent and orally activeHIF prolyl hydroxylase 2 inhibitors for the treatment of anemia. YueWu, Linjian Zhang, Zhuoli Sun, Xusheng Qiu, Yafen Chen, KaijunSu, Le Yang, Zhongqiu Du, Ying Dong, Fulai Yang, Xiang Li,Xiaojin Zhang. Journal of Medicinal Chemistry2023, 66 (13), 8545–8563https://doi.org/10.1021/acs.jmedchem.3c00231

8.      Insitu inhibitor synthesis and screening by fluorescence polarization:an efficient approach for accelerating drug discovery. Zhihong Li,Yue Wu, Shuai Zhen, Kaijun Su, Linjian Zhang, Fulai Yang, Michael A.McDonough, Christopher J. Schofield, Xiaojin Zhang.Angewandte Chemie International Edition2022, 61 (45), e202211510 (IF=16.8)https://doi.org/10.1002/anie.202211510

9.      Acarbon-carbon bond cleavage–based prodrug activation strategyapplied to β-lapachone for cancer-specific targeting. Qijie Gong,Xiang Li, Tian Li, Xingsen Wu, Jiabao Hu, Fulai Yang, Xiaojin Zhang.Angewandte Chemie International Edition2022, 61 (40), e202210001 (IF=16.8)https://doi.org/10.1002/anie.202210001

10.   Discovery of a potentand orally bioavailable hypoxia-inducible factor 2α (HIF-2α)agonist and its synergistic therapy with prolyl hydroxylaseinhibitors for the treatment of renal anemia. Yancheng Yu, FulaiYang, Quanwei Yu, Simeng Liu, Chenyang Wu, Kaijun Su, Le Yang,Xiaoqian Bao, Zhihong Li, Xiang Li, XiaojinZhang. Journal of Medicinal Chemistry2021, 64 (23), 17384–17402 (cover)https://doi.org/10.1021/acs.jmedchem.1c01479